To download a PDF of the programme click here.
For further information on this event please contact us.
Day One
Tuesday 27th June 2023
08.15 onwards
Registration and Poster Set-Up
09.45-10.00
Welcome to Riga and Opening Remarks
Kaspars Tars
(Latvian Biomedical Research and Study Center, Riga, Latvia)
SESSION 1:
OPENING PLENARY SESSION
Moderator: Kaspars Tars
(Latvian Biomedical Research and Study Center, Riga, Latvia)
10.00-10.40
KEYNOTE:
‘Pushing the envelope of HIV-1 vaccine design’
Richard Wyatt
(Scripps Research Institute, La Jolla, California, USA)
10.40-11.20
‘Malaria Vaccines targeting vulnerable epitopes in CSP’
Lucie Jelinkova1, Yevel Flores-Garcia2, Yogesh Nepal1, Bryce Roberts1, Alexandra Francian1, Rabia Khan1, Fidel Zavala2 and Bryce Chackerian1
(1 University of New Mexico School of Medicine, Albuquerque, New Mexico, USA; 2 Johns Hopkins University, Baltimore, Maryland, USA)
11.20-12.00
Coffee Break & Posters
12.00-12.30
KEYNOTE:
‘Polio and the need for non infectious vaccines such as VLPs’
Martin Eisenhauer
(World Health Organisation, Geneva, Switzerland)
12.30-13.00
KEYNOTE:
‘A next generation Alzheimers vaccine’
Martin Bachmann
(University of Bern, Bern, Switzerland/University of Oxford, Oxford, UK)
13.00-14.00
Lunch Break & Posters
SESSION 2:
DESIGN/DEVELOPMENT/PRODUCTION
Moderator: Bryce Chackerian
(University of New Mexico School of Medicine, Albuquerque, New Mexico, USA)
14.00-14.30
‘VLPs of ssRNA phages: Diversity, structure and applications in vaccine development’
Kaspars Tars
(Latvian Biomedical Research and Study Center, Riga, Latvia)
14.30-15.00
‘Design of hepatitis B virus-like particles (VLPs) to optimise immunisation outcomes for preventative or therapeutic applications
Hans Netter
(Peter Doherty Institute, Melbourne, Victoria, Australia)
15.00-15.30
‘Polio VLP development consortium presentation’
Nicola Stonehouse
(University of Leeds, Leeds, UK)
15.30-16.00
Tea Break & Posters
SESSION 3:
VLP VACCINES
Moderator: Martin Eisenhauer
World Health Organisation WHO, Geneva, Switzerland)
16.00-16.30
KEYNOTE:
‘VLP-based vaccines for cardiovascular disease’
Alexandra Fowler1, Erin Crossey1, Maureen Sampson2, Marcelo Amar2, John Schiller3, Koen Van Rompay4, Alan Remaley2 and Bryce Chackerian1
(1 University of New Mexico School of Medicine, Albuquerque, New Mexico, USA; 2 NIH/NHLBI, Bethesda, Maryland, USA; 3 NIH/NCI, Bethesda, Maryland, USA; 4 California Regional Primate Center, Davis, California, USA)
16.30-17.00
‘Expression and evaluation of coat proteins derived from thermophilic bacteriophages for assembly into virus-like particles’
Lukai Zhai1,2, Rashi Yadav1,3 and Ebenezer Tumban1,4
( 1 Michigan Technological University, Houghton, Michigan, USA; 2 Current address: Department of metabolism and nutritional programming, Van Andel Research Institute, Grand Rapids, Michigan, USA; 3 Current address: Oregon Health and Science University, Portland, Oregon, USA: 4 Current address: Texas Tech University School of Veterinary Medicine, Amarillo, Texas, USA)
17.00-17.30
‘Exploiting Pichia pastoris for production of a VLP vaccine against poliomyelitis’
Jessica Swanson1, Lee Sherry1, Keith Grehan1, Kirsty Sawtell1, Helen Fox2, Mohammad W. Bahar3, Elizabeth E. Fry3, David I. Stuart3, Andrew J. Macadam2, David J. Rowlands1 and Nicola J. Stonehouse1
(1 School of Molecular and Cellular Biology, University of Leeds, Leeds, UK; 2 Division of Virology, National Institute for Biological Standards and Control, South Mimms, Potters Bar, UK; 3 Division of Structural Biology, University of Oxford, Oxford, UK)
17.30-17.50
‘POLIO ALERT – An Old Disease resurfaces in the world’
Micha Roumiantzeff, Joël Calmet and Konstantin Chumakov
(Michadvices, Lyon, France)
17.50-19.00
VLPNPV 2023 Welcome Drinks Reception & Posters
Sponsored by BIOSAN
Day Two
Wednesday 28th June 2023
SESSION 4:
PLANT-BASED VLPS
Moderator: George Lomonossoff
(John Innes Centre, Norwich Research Park, Norwich, UK)
09.00-09.30
‘Plant VLPs in vaccine development’
Andris Zeltins
(Latvian Biomedical Research and Study Center, Riga, Latvia)
09.30-10.00
‘Plant based norovirus VLPs: From molecule design to phase I clinical trials’
Stefan Werner and Franziska Jarczowski
(Icon Genetics GmbH, Halle (Saale), Germany)
10.00-10.30
‘The use of cowpea mosaic virus capsids to stabilise and deliver designer RNA molecules’
H. Peyret, J-W. Jung, S.N. Shah, Y. Meshcheriakova, G.P. Lomonossoff
(John Innes Centre, Norwich Research Park, Norwich, UK)
10.30-11.00
Coffee Break & Posters
SESSION 5:
Moderator: Nicola Stonehouse
(University of Leeds, Leeds, UK)
11.00-11.30
KEYNOTE:
‘Next Generation HIV Envelope Glycoprotein Trimers’
Richard Wyatt
(Scripps Research Institute, La Jolla, California, USA)
11.30-12.00
‘Vaccines by affinity selection on MS2 VLPs’
David Peabody and Bryce Chackerian
(University of New Mexico, Albuquerque, New Mexico, USA)
12.00-12.30
‘A novel platform to manufacture Virus-like Particles fully decorated with natively folded epitope in a single cell-bank’
John Foerster, Aleksandra Moleda1, Jonas Repkewitz2, Kaniz Fatema, Billie Pflug and Jean-Christophe Bourdon
(University of Dundee, School of Medicine, Dundee, Scotland, UK; 1 Present address: Allergy Therapeutics, Worthing, West Sessex, UK; 2 Present address: Royal London Hospital, Bart’s Health NHS Trust, London, UK)
12.30-13.00
‘Quality by design applied to the development of GMMA based vaccines’
D. Oldrini1, V. Arato1, E. Palmieri1, G. Gasperini2, M.M. Raso1, E. Bartolini2, I. Pisoni2, F. Necchi1, C. Giannelli1, C. Campa2 and F. Micoli1
(1 GSK Vaccines Institute for Global Health, Via Fiorentina 1, Siena, Italy; 2 GSK Vaccines, Via Fiorentina 1, Siena, Italy)
13.00-14.00
Lunch Break & Posters
SESSION 6:
Moderator: Martin Bachmann
(University of Berne, Berne, Switzerland)
14.00-14.30
‘Exploiting hepatitis B core protein VLPs for the presentation of glycoprotein fragments‘
Keith Grehan, Jehad Alzahrani, Khalid Alluhaybi, Pedro Martin Reyes, Natalie Kingston, Kaniz Fatema, Martin Stacey, David J. Rowlands and Nicola J. Stonehouse
(School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK)
14.30-15.00
‘Pharmaceutical development of a novel therapeutic against peanut allergy (VLP Peanut)’
Matthew Heath and Alexsandra Moleda
(Allergy Therapeutics (UK) Ltd, Worthing,West Sussex, UK)
15.00-15.30
‘Production of SARS-CoV-2 VLPs in plants for use as virus surrogates’
J-W. Jung1, Y. Meshcheriakova1, G. Zahmanova2,3, I. Minkov3, J. Balieu4, M. Bardor4, P. Lerouge4, K. Goritzer5, J-K. Ma5 and G.P. Lomonossoff1
(1 Department of Biochemistry and Metabolism, John Innes Centre, Colney, UK; 2 Department of Plant Physiology and Molecular Biology, University of Plovdiv, Plovdiv, Bulgaria; 3 Center of Plant Systems Biology and Biotechnology, Plovdiv, Bulgaria; 4 Université de Rouen Normandie, Laboratoire Glyco-MEV UR 4358, SFR Normandie Végétal FED 4277, Innovation Chimie Carnot, Rouen, France; 5 St. George’s Hospital, University of London, London, UK)
15.30-16.00
Tea Break & Posters
SESSION 7:
VLP VACCINES
Moderator: Hans Netter
(Peter Doherty Institute, Melbourne, Victoria, Australia)
16.00-16.30
KEYNOTE:
‘Virus-like nanoparticles for developing therapeutic cancer vaccines, from bench to bedside’
Mona O. Mohsen
(University of Bern, Bern, Switzerland)
16.30-17.00
‘HIV-1 fusion peptide displayed on self-assembling nanoparticles for genetic immunization’
Baoshan Zhang
(NIH, Bethesda, Maryland, USA)
17.00-17.30
‘Bacteriophage virus-like particle vaccines for opioids’
Kathryn M. Frietze and Isabella Romano
(University of New Mexico School of Medicine, Albuquerque, New Mexico, USA)
17.30-18.00
‘From research to GMP – When quality comes into play’
F. Jarczowski, A. Diessner and V. Klimyuk
(Icon Genetics GmbH, Halle (Saale), Germany)
Day Three
Thursday 29th June 2023
SESSION 8:
Moderator: John Foerster
(University of Dundee, Dundee, Scotland, UK)
09.00-09.30
‘A Human Immune System-humanized mouse model for testing virus-like particle and nanoparticle vaccine candidates in infectious diseases’
Teodor-D. Brumeanu1, Faisal A. Karim2, Sounak G. Roy2, Sofia A. Casares1,2
(1 Department of Medicine, Division of Immunology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA; 2 Infectious Diseases Directorate, Naval Medical Research Center, Silver Spring, Maryland, USA)
09.30-10.00
‘Bioparticle-potentiated immunotherapy combines potent immune activation and hypoallergenicity for cat allergy treatment‘
Veronique Gomord, Loic Faye, B. Morel et al.
(ANGANY innovation, Val de reuil, France)
10.00-10.30
‘Efficacy of S1 nanoparticle vs. subunit vaccines against SARS-CoV-2 challenge in K18-hACE2 mice’
Linda van Oosten1, Kexin Yan2, Daniel J. Rawle2, Thuy T Le2, Jort J. Altenburg3, Cyrielle Fougeroux4, Louise Goksøyr4,5, Willem Adriaan de Jongh4, Morten A. Nielsen5, Adam F. Sander4,5, Gorben P. Pijlman1 and Andreas Suhrbier2,6
(1 Wageningen University, Wageningen, The Netherlands; 2 QIMR Berghofer Medical Research Institute, Brisbane, Australia; 3 Bioprocess Engineering, Wageningen University, Wageningen, The Netherlands; 4 AdaptVac Aps, Hørsholm, Denmark; 5 University of Copenhagen, Copenhagen, Denmark; 6 GVN Center of Excellence, Australian Infectious Disease Research Centre, Brisbane, Australia)
10.30-11.00
Coffee Break & Posters Breakdown
SESSION 9:
LATEBREAKER PRESENTATIONS
Moderator: Kaspars Tars
(Latvian Biomedical Research and Study Center, Riga, Latvia)
11.00-11.30
‘Comparative efficacy of Mayaro virus-like particle vaccines produced in insect or mammalian cells’
Sandra R. Abbo1, Wilson Nguyen2, Marleen H.C. Abma-Henkens1, Denise van de Kamer1, Niek H.A. Savelkoul1, Corinne Geertsema1, Thuy T.T. Le2, Bing Tang2, Kexin Yan2, Troy Dumenil2, Monique M. van Oers1, Andreas Suhrbier2,3 and Gorben P. Pijlman1
(1 Laboratory of Virology, Wageningen University & Research, Wageningen, The Netherlands; 2 Inflammation Biology Group, QIMR Berghofer Medical Research Institute, Brisbane, Qld., Australia; 3 GVN Center of Excellence, Australian Infectious Disease Research Center, Brisbane, Qld., Australia)
11.30-12.00
‘Utilizing a replicating virus vector to encapsidate designer RNA into capsids of differing morphology’
Keith Saunders, Sachin Shah, Hadrien Peyret, Eva C. Thuenemann and George P. Lomonossoff
(John Innes Centre, Norwich Research Park, Norwich, UK)
12.00-12.20
‘Development of a therapeutic vaccine candidate for HPV’
Jenna Bloemetje
(University of Capetown, Rondebosch, Capetown, South Africa)
12.20-12.35
Poster 101 (Short Oral Presentation)
‘Exploring different self-assembling nanoparticles in displaying vaccine antigens’
L. Cappelli
(GSK, Siena, Italy)
12.35-12.50
Poster 105 (Short Oral Presentation)
‘Enhancing Anti-SARS-CoV-2 neutralizing immunity in mice by immunization with enveloped virus-like particles displaying SARS-CoV-2 spikes’
Yongping Yang
(Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, Maryland, USA)
12.50
Closing Remarks by VLPNPV 2023 Chairman
Kaspars Tars
(Latvian Biomedical Research and Study Center, Riga, Latvia)
Lunch & Departure
Posters
Poster 101
‘Exploring different self‐assembling nanoparticles in displaying vaccine antigens’
L. Cappelli, P. Cinelli, N. Wahome, F. Giusti, F. Carboni, I. Delany, D. Maione, E. Frigimelica and R. Cozzi
(GSK, Siena, Italy)
Poster 102
‘In vitro self-assembling protein nanoparticles as carriers for glycoconjugate vaccines development’
Marta Dolce1,2, Giusy Manuela Adamo1, Daniela Proietti1, Sara Favaron1,3, Elia Ferri1, Fabiola Giusti1, Immaculada Margarit y Ros1, Maria Rosaria Romano1, Maria Scarselli1 and Filippo Carboni1
(1 GSK, Siena, Italy, 2 Università di Siena, Siena, Italy, 3 Politecnico di Milano, Milano, Italy)
Poster 103
‘Modifications on HBcAg VLPs to dually display two different peptides on the same VLP by using Affimers capturing system’
Khalid Alluhaybi
(University of Leeds, Leeds, Yorkshire, UK)
Poster 104
‘Therapeutic vaccines based on virus-like particle technology for the treatment of neurodegenerative diseases – Alzheimer’s and Lewy body disorders’
I. Liekniņa, M. Šasko and K. Tārs
(Latvian Biomedical Research and Study Centre, University of Latvia, Riga, Latvia)
Poster 105
‘Enhancing Anti-SARS-CoV-2 neutralizing immunity in mice by immunization with enveloped virus-like particles displaying SARS-CoV-2 spikes’
Yongping Yang
(Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, Maryland, USA)
Poster 106
‘Robust production of virus-like particles in CHO-K1 and HEK293 cell lines’
Frank Richter
(Roche Diagnostics GmbH, Penzberg, Bavaria, Germany)
Poster 107
‘Separation of T=3 and T=4 assembles of hepatitis B capsid VLPs by liquid chromatography’
Pedro Martin-Reyes
(University of Leeds, Leeds, UK)
Poster 108
‘Bacterial expression systems based on plant virus-like particles for the presentation of vaccine antigens’
Anete Ogrina
(Latvian Biomedical Research and Study Centre, University of Latvia, Riga, Latvia)
Poster 109
‘Mode of action of nanoparticles as carriers for bacterial glycoconjugate vaccines’
Camilla Senese
(University of Siena, Siena, Italy; GSK, Siena, Italy)
Poster 110
‘Pichia pastoris expression system as tool for ryegrass mottle virus coat protein virus-like particle assembly’
Ina Balke, Gunta Resevica, Vilija Zeltina, Elva Liepa, Reinis Liepa, Ieva Kalnciema, Janis Freivalds, Andris Kazaks and Andris Zeltins
(Latvian Biomedical Research and Study Centre, University of Latvia, Riga, Latvia)
This final programme is correct at the time of publication. However the organizers reserve the right to make any alterations that may be required in the interests and integrity of the conference programme.